Merck Serono S. A.

The University of Texas System

Golgi Neurosciences S.r.l.

Elixir Pharmaceuticals, Inc.

Applied Research Systems Ars Holding N.v.

Laboratoires Serono S.a.

Siena Biotech S.p.a.

Axxam S.p.a.

Rodin Therapeutics, Inc.

Aop Orphan Pharmaceuticals Ag

Breye Therapeutics Aps

Russell Thomas

Matthias Schwarz

Paolo Pevarello

Valentina Cusano

Domenica Torino

Francesco Piscitelli

Ali Munaim Yousif

Philip Jones

Anna Quattropani

Patrick Naxos Page

Chiara Liberati

William J Ray

Silvia Bovolenta

Yaima Luzardo Lightfoot

Mary Hamby

Andreas Goutopoulos

Catherine Jorand-Lebrun

Yihua Liao

Sharad Magar

Jean-Francois Pons

Andrew Napper

Peter DiStefano

Rory A Curtis

Rocco Vitalone

Jeffrey O Saunders

Jay R Luly

Fabian Dey

Vincent Pomel

Jean-Pierre Gotteland

Martin R Jefson

Manuel A Navia

Pascale Gaillard

Serge Halazy

Thomas Stephen Coulter

Thomas E McDonagh

Andreas Schoop

Jonathan M Solomon

L Julie Huber

Alexander Scheer

Anthony David Baxter

Annette Cornelia Bakker

Galla Pericot Mohr

Giacomo Minetto

Adrian Schomburg

Pietro Ferruzzi

Jeffrey Hixon

Enrica Diodato

Katia Marcucci

Estelle Hamelin

Paul Wiedenau

Martin Rettig

Huw Roberts

Andrew Griffin

Mariangela Sodano

Elda Severi

Konstanze Konig Von Paumbshausen

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Bicyclic CX3CR1 receptor agonists

Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and to a process for the preparation of the compounds: Ris independently selected from hydrogen atom, amine group, monocyclic or bicyclic aliphatic, aromatic, heteroaliphatic or heteroaromatic ring. Ris independently selected from monocyclic or bicylic aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, C-Calkyl, alkenyl or alkynyl chain. n is 1 or 2; preferably n is 1. m is 0, 1 or 2; preferably m is 0. Rand Rcan be, independently, &#x2014;H, &#x2014;F, C-Calkyl, &#x2014;OH, &#x2014;OC-Calkyl; preferably they are both &#x2014;H. X is O or S. Ris &#x2014;H or &#x2014;CHoptionally substituted by one or more fluorine atoms; preferably Ris hydrogen. The compounds can be used in the treatment of conditions or diseases mediated by P2X7 receptor.

Heterocyclic P2X7 antagonists

Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof: These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. Also disclosed are pharmaceutical compositions including these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.

Substituted pyrazoles FFA4/GPR120 receptor agonists

The invention relates to a novel process for the preparation of rac-6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (I) in pharmaceutically acceptable polymorphic form, through the conversion of a 3-bromo-2-oxo-cyclohexanecarboxylic acid alkyl ester into 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid alkyl ester, which in turn is processed to yield the final product.

Process for the preparation of 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and intermediates thereof

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Inhibitors of histone deacetylase

The invention provides 2-carboxamide piperazine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.

Piperazine derivatives and methods of use

Heterocyclic compounds that modulate the hedgehog signaling pathway, pharmaceutical composition thereof and their therapeutic applications.

Hedgehog pathway antagonists and therapeutic applications thereof

Compound of formula (I) and methods of treating disorders by administering a compound of formula (I) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders.

SirT inhibitors that bind to NAD

The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. 

Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor

The present invention is related to piperazine-2-carboxamide derivatives of formula (I) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X, Y, Rand Rare as defined in the description. 

Piperazine-2-carboxamide derivatives

Compounds of formula (I) are described herein  The compounds can be used, for example, to modulate growth hormone secretagogue receptor (GHS-R). In some instances, the compounds can be used to treat obesity.

Therapeutic compounds and uses thereof

The present invention is related to pyridinyl acetonitriles as well as to pharmaceutical formulations containing such pyridinyl acetonitriles. Said pyridinyl acetonitriles are modulators of the protein kinase signalling pathways, particularly the one involving Glycogen Kinase Synthase 3 or JNK. The present invention is furthermore related to methods of preparing pyridinyl acetonitriles. X is a substituted or unsubstituted pyridinyl. G is an unsubstituted or substituted pyrimidinyl or triazinyl.

Pyridinyl acetonitriles

The invention provides 2-carboxamide piperazine compounds of formula I, R.IN\'N&#x2dc;&#x2032;RI(0)z-oRI wherein R&#x2032;, R, Rand Rare as defined in the claims and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.

Growing community of inventors

Siena, Italy

Russell Thomas